Bristol-Myers Squibb Company PFD CONV 2 Logo

Bristol-Myers Squibb Company PFD CONV 2

BMYMP

(1.8)
Stock Price

998,89 USD

-15.19% ROA

-36.26% ROE

-246.67x PER

Market Cap.

109.260.977.064,00 USD

308.94% DER

0.33% Yield

-15.3% NPM

Bristol-Myers Squibb Company PFD CONV 2 Stock Analysis

Bristol-Myers Squibb Company PFD CONV 2 Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Bristol-Myers Squibb Company PFD CONV 2 Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (26.76%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

4 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (3.772) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (46.93x) suggests it's overvalued, potentially making it an expensive investment.

6 DER

The company has a high debt to equity ratio (135%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Bristol-Myers Squibb Company PFD CONV 2 Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Bristol-Myers Squibb Company PFD CONV 2 Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Sell
4 Stoch RSI Hold

Bristol-Myers Squibb Company PFD CONV 2 Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Bristol-Myers Squibb Company PFD CONV 2 Revenue
Year Revenue Growth
1987 7.558.000.000
1988 8.558.000.000 11.68%
1989 9.189.000.000 6.87%
1990 10.300.000.000 10.79%
1991 11.159.000.000 7.7%
1992 11.156.000.000 -0.03%
1993 11.413.000.000 2.25%
1994 11.984.000.000 4.76%
1995 13.767.000.000 12.95%
1996 15.065.000.000 8.62%
1997 16.701.000.000 9.8%
1998 18.284.000.000 8.66%
1999 20.222.000.000 9.58%
2000 18.216.000.000 -11.01%
2001 19.423.000.000 6.21%
2002 18.119.000.000 -7.2%
2003 20.894.000.000 13.28%
2004 19.380.000.000 -7.81%
2005 19.207.000.000 -0.9%
2006 17.914.000.000 -7.22%
2007 19.348.000.000 7.41%
2008 20.597.000.000 6.06%
2009 18.808.000.000 -9.51%
2010 19.484.000.000 3.47%
2011 21.244.000.000 8.28%
2012 17.621.000.000 -20.56%
2013 16.385.000.000 -7.54%
2014 15.879.000.000 -3.19%
2015 16.560.000.000 4.11%
2016 19.427.000.000 14.76%
2017 20.776.000.000 6.49%
2018 22.561.000.000 7.91%
2019 26.145.000.000 13.71%
2020 42.518.000.000 38.51%
2021 46.385.000.000 8.34%
2022 46.159.000.000 -0.49%
2023 43.864.000.000 -5.23%
2023 45.006.000.000 2.54%
2024 48.804.000.000 7.78%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Bristol-Myers Squibb Company PFD CONV 2 Research and Development Expenses
Year Research and Development Expenses Growth
1987 0
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 1.108.000.000 100%
1995 1.199.000.000 7.59%
1996 1.276.000.000 6.03%
1997 1.385.000.000 7.87%
1998 1.577.000.000 12.18%
1999 1.843.000.000 14.43%
2000 1.939.000.000 4.95%
2001 2.259.000.000 14.17%
2002 2.218.000.000 -1.85%
2003 2.279.000.000 2.68%
2004 2.500.000.000 8.84%
2005 2.746.000.000 8.96%
2006 3.067.000.000 10.47%
2007 3.282.000.000 6.55%
2008 3.585.000.000 8.45%
2009 3.647.000.000 1.7%
2010 3.566.000.000 -2.27%
2011 3.839.000.000 7.11%
2012 3.904.000.000 1.66%
2013 3.731.000.000 -4.64%
2014 4.534.000.000 17.71%
2015 5.920.000.000 23.41%
2016 4.940.000.000 -19.84%
2017 6.411.000.000 22.94%
2018 6.345.000.000 -1.04%
2019 6.148.000.000 -3.2%
2020 11.143.000.000 44.83%
2021 10.195.000.000 -9.3%
2022 9.509.000.000 -7.21%
2023 8.968.000.000 -6.03%
2023 9.299.000.000 3.56%
2024 9.180.000.000 -1.3%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Bristol-Myers Squibb Company PFD CONV 2 General and Administrative Expenses
Year General and Administrative Expenses Growth
1987 0
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 3.903.000.000 100%
2002 3.923.000.000 0.51%
2003 4.660.000.000 15.82%
2004 5.016.000.000 7.1%
2005 5.106.000.000 1.76%
2006 4.919.000.000 -3.8%
2007 4.855.000.000 -1.32%
2008 4.825.000.000 -0.62%
2009 4.078.000.000 -18.32%
2010 3.559.000.000 -14.58%
2011 4.203.000.000 15.32%
2012 158.000.000 -2560.13%
2013 165.000.000 4.24%
2014 877.000.000 81.19%
2015 160.000.000 -448.13%
2016 91.000.000 -75.82%
2017 162.000.000 43.83%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Bristol-Myers Squibb Company PFD CONV 2 EBITDA
Year EBITDA Growth
1987 1.415.000.000
1988 1.763.000.000 19.74%
1989 1.022.000.000 -72.5%
1990 2.441.000.000 58.13%
1991 2.835.000.000 13.9%
1992 2.179.000.000 -30.11%
1993 2.486.000.000 12.35%
1994 4.271.000.000 41.79%
1995 5.318.000.000 19.69%
1996 4.429.000.000 -20.07%
1997 4.973.000.000 10.94%
1998 6.532.000.000 23.87%
1999 6.594.000.000 0.94%
2000 7.289.000.000 9.53%
2001 10.252.000.000 28.9%
2002 6.395.000.000 -60.31%
2003 5.928.000.000 -7.88%
2004 5.487.000.000 -8.04%
2005 4.448.000.000 -23.36%
2006 3.784.000.000 -17.55%
2007 4.757.000.000 20.45%
2008 5.971.000.000 20.33%
2009 4.311.000.000 -38.51%
2010 6.575.000.000 34.43%
2011 7.126.000.000 7.73%
2012 4.360.000.000 -63.44%
2013 3.230.000.000 -34.98%
2014 2.134.000.000 -51.36%
2015 2.434.000.000 12.33%
2016 5.617.000.000 56.67%
2017 5.718.000.000 1.77%
2018 6.071.000.000 5.81%
2019 6.599.000.000 8%
2020 14.816.000.000 55.46%
2021 20.182.000.000 26.59%
2022 19.923.000.000 -1.3%
2023 19.836.000.000 -0.44%
2023 19.177.000.000 -3.44%
2024 20.580.000.000 6.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Bristol-Myers Squibb Company PFD CONV 2 Gross Profit
Year Gross Profit Growth
1987 5.417.000.000
1988 6.259.000.000 13.45%
1989 6.729.000.000 6.98%
1990 7.670.000.000 12.27%
1991 8.475.000.000 9.5%
1992 8.594.000.000 1.38%
1993 8.692.000.000 1.13%
1994 9.190.000.000 5.42%
1995 10.578.000.000 13.12%
1996 11.619.000.000 8.96%
1997 12.828.000.000 9.42%
1998 14.053.000.000 8.72%
1999 15.361.000.000 8.52%
2000 14.203.000.000 -8.15%
2001 13.848.000.000 -2.56%
2002 11.731.000.000 -18.05%
2003 13.302.000.000 11.81%
2004 13.391.000.000 0.66%
2005 13.279.000.000 -0.84%
2006 11.958.000.000 -11.05%
2007 13.130.000.000 8.93%
2008 14.201.000.000 7.54%
2009 13.668.000.000 -3.9%
2010 14.207.000.000 3.79%
2011 15.646.000.000 9.2%
2012 13.011.000.000 -20.25%
2013 11.766.000.000 -10.58%
2014 11.947.000.000 1.52%
2015 12.651.000.000 5.56%
2016 14.481.000.000 12.64%
2017 14.710.000.000 1.56%
2018 16.014.000.000 8.14%
2019 18.067.000.000 11.36%
2020 30.745.000.000 41.24%
2021 36.445.000.000 15.64%
2022 36.022.000.000 -1.17%
2023 33.840.000.000 -6.45%
2023 34.313.000.000 1.38%
2024 27.204.000.000 -26.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Bristol-Myers Squibb Company PFD CONV 2 Net Profit
Year Net Profit Growth
1987 1.068.000.000
1988 1.254.000.000 14.83%
1989 747.000.000 -67.87%
1990 1.748.000.000 57.27%
1991 2.056.000.000 14.98%
1992 1.962.000.000 -4.79%
1993 1.959.000.000 -0.15%
1994 1.842.000.000 -6.35%
1995 1.812.000.000 -1.66%
1996 2.850.000.000 36.42%
1997 3.205.000.000 11.08%
1998 3.141.000.000 -2.04%
1999 4.167.000.000 24.62%
2000 4.711.000.000 11.55%
2001 5.245.000.000 10.18%
2002 2.066.000.000 -153.87%
2003 3.106.000.000 33.48%
2004 2.388.000.000 -30.07%
2005 3.000.000.000 20.4%
2006 1.585.000.000 -89.27%
2007 2.165.000.000 26.79%
2008 5.247.000.000 58.74%
2009 10.612.000.000 50.56%
2010 3.102.000.000 -242.1%
2011 3.709.000.000 16.37%
2012 1.960.000.000 -89.23%
2013 2.563.000.000 23.53%
2014 2.004.000.000 -27.89%
2015 1.624.000.000 -23.4%
2016 4.457.000.000 63.56%
2017 1.007.000.000 -342.6%
2018 4.952.000.000 79.66%
2019 3.439.000.000 -44%
2020 -8.995.000.000 138.23%
2021 6.994.000.000 228.61%
2022 6.327.000.000 -10.54%
2023 7.712.000.000 17.96%
2023 8.025.000.000 3.9%
2024 6.720.000.000 -19.42%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Bristol-Myers Squibb Company PFD CONV 2 Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1987 1
1988 1 0%
1989 0 0%
1990 1 100%
1991 1 0%
1992 1 0%
1993 1 0%
1994 1 0%
1995 1 0%
1996 2 0%
1997 2 0%
1998 2 0%
1999 3 50%
2000 3 0%
2001 3 33.33%
2002 1 -200%
2003 2 0%
2004 1 0%
2005 2 0%
2006 1 0%
2007 1 100%
2008 3 66.67%
2009 6 50%
2010 2 -500%
2011 2 50%
2012 1 -100%
2013 2 0%
2014 1 0%
2015 1 0%
2016 3 100%
2017 1 0%
2018 3 100%
2019 2 -50%
2020 -4 166.67%
2021 3 200%
2022 3 -50%
2023 4 33.33%
2023 4 0%
2024 3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Bristol-Myers Squibb Company PFD CONV 2 Free Cashflow
Year Free Cashflow Growth
1989 635.000.000
1990 1.239.000.000 48.75%
1991 1.207.000.000 -2.65%
1992 1.381.000.000 12.6%
1993 2.010.000.000 31.29%
1994 1.728.000.000 -16.32%
1995 1.986.000.000 12.99%
1996 2.040.000.000 2.65%
1997 1.709.000.000 -19.37%
1998 3.332.000.000 48.71%
1999 3.761.000.000 11.41%
2000 4.063.000.000 7.43%
2001 4.379.000.000 7.22%
2002 -40.000.000 11047.5%
2003 2.522.000.000 101.59%
2004 2.367.000.000 -6.55%
2005 1.098.000.000 -115.57%
2006 1.290.000.000 14.88%
2007 2.310.000.000 44.16%
2008 2.766.000.000 16.49%
2009 3.335.000.000 17.06%
2010 4.067.000.000 18%
2011 4.473.000.000 9.08%
2012 6.393.000.000 30.03%
2013 3.008.000.000 -112.53%
2014 2.622.000.000 -14.72%
2015 1.012.000.000 -159.09%
2016 1.635.000.000 38.1%
2017 4.220.000.000 61.26%
2018 4.989.000.000 15.41%
2019 7.231.000.000 31.01%
2020 13.299.000.000 45.63%
2021 15.234.000.000 12.7%
2022 11.948.000.000 -27.5%
2023 12.651.000.000 5.56%
2023 4.409.000.000 -186.94%
2024 2.064.000.000 -113.61%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Bristol-Myers Squibb Company PFD CONV 2 Operating Cashflow
Year Operating Cashflow Growth
1989 1.190.000.000
1990 1.752.000.000 32.08%
1991 1.835.000.000 4.52%
1992 2.028.000.000 9.52%
1993 2.580.000.000 21.4%
1994 2.301.000.000 -12.13%
1995 2.499.000.000 7.92%
1996 2.641.000.000 5.38%
1997 2.476.000.000 -6.66%
1998 4.120.000.000 39.9%
1999 4.470.000.000 7.83%
2000 4.652.000.000 3.91%
2001 5.402.000.000 13.88%
2002 957.000.000 -464.47%
2003 3.512.000.000 72.75%
2004 3.176.000.000 -10.58%
2005 1.836.000.000 -72.98%
2006 2.083.000.000 11.86%
2007 3.153.000.000 33.94%
2008 3.707.000.000 14.94%
2009 4.065.000.000 8.81%
2010 4.491.000.000 9.49%
2011 4.840.000.000 7.21%
2012 6.941.000.000 30.27%
2013 3.545.000.000 -95.8%
2014 3.148.000.000 -12.61%
2015 1.832.000.000 -71.83%
2016 2.850.000.000 35.72%
2017 5.275.000.000 45.97%
2018 5.940.000.000 11.2%
2019 8.067.000.000 26.37%
2020 14.052.000.000 42.59%
2021 16.207.000.000 13.3%
2022 13.066.000.000 -24.04%
2023 13.860.000.000 5.73%
2023 4.751.000.000 -191.73%
2024 2.326.000.000 -104.26%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Bristol-Myers Squibb Company PFD CONV 2 Capital Expenditure
Year Capital Expenditure Growth
1989 555.000.000
1990 513.000.000 -8.19%
1991 628.000.000 18.31%
1992 647.000.000 2.94%
1993 570.000.000 -13.51%
1994 573.000.000 0.52%
1995 513.000.000 -11.7%
1996 601.000.000 14.64%
1997 767.000.000 21.64%
1998 788.000.000 2.66%
1999 709.000.000 -11.14%
2000 589.000.000 -20.37%
2001 1.023.000.000 42.42%
2002 997.000.000 -2.61%
2003 990.000.000 -0.71%
2004 809.000.000 -22.37%
2005 738.000.000 -9.62%
2006 793.000.000 6.94%
2007 843.000.000 5.93%
2008 941.000.000 10.41%
2009 730.000.000 -28.9%
2010 424.000.000 -72.17%
2011 367.000.000 -15.53%
2012 548.000.000 33.03%
2013 537.000.000 -2.05%
2014 526.000.000 -2.09%
2015 820.000.000 35.85%
2016 1.215.000.000 32.51%
2017 1.055.000.000 -15.17%
2018 951.000.000 -10.94%
2019 836.000.000 -13.76%
2020 753.000.000 -11.02%
2021 973.000.000 22.61%
2022 1.118.000.000 12.97%
2023 1.209.000.000 7.53%
2023 342.000.000 -253.51%
2024 262.000.000 -30.53%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Bristol-Myers Squibb Company PFD CONV 2 Equity
Year Equity Growth
1987 4.755.000.000
1988 4.948.000.000 3.9%
1989 5.084.000.000 2.68%
1990 5.418.000.000 6.16%
1991 5.795.000.000 6.51%
1992 6.020.000.000 3.74%
1993 5.940.000.000 -1.35%
1994 5.704.000.000 -4.14%
1995 5.822.000.000 2.03%
1996 6.570.000.000 11.39%
1997 7.219.000.000 8.99%
1998 7.576.000.000 4.71%
1999 8.645.000.000 12.37%
2000 9.180.000.000 5.83%
2001 10.736.000.000 14.49%
2002 8.967.000.000 -19.73%
2003 9.786.000.000 8.37%
2004 10.202.000.000 4.08%
2005 11.208.000.000 8.98%
2006 9.991.000.000 -12.18%
2007 10.562.000.000 5.41%
2008 12.241.000.000 13.72%
2009 14.785.000.000 17.21%
2010 15.638.000.000 5.45%
2011 15.867.000.000 1.44%
2012 13.638.000.000 -16.34%
2013 15.236.000.000 10.49%
2014 14.983.000.000 -1.69%
2015 14.424.000.000 -3.88%
2016 16.347.000.000 11.76%
2017 11.847.000.000 -37.98%
2018 14.127.000.000 16.14%
2019 51.698.000.000 72.67%
2020 37.882.000.000 -36.47%
2021 36.006.000.000 -5.21%
2022 31.118.000.000 -15.71%
2023 29.485.000.000 -5.54%
2023 29.062.000.000 -1.46%
2024 17.069.000.000 -70.26%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Bristol-Myers Squibb Company PFD CONV 2 Assets
Year Assets Growth
1987 7.514.000.000
1988 8.273.000.000 9.17%
1989 8.497.000.000 2.64%
1990 9.215.000.000 7.79%
1991 9.416.000.000 2.13%
1992 10.804.000.000 12.85%
1993 12.101.000.000 10.72%
1994 12.910.000.000 6.27%
1995 13.929.000.000 7.32%
1996 14.685.000.000 5.15%
1997 14.977.000.000 1.95%
1998 16.272.000.000 7.96%
1999 17.114.000.000 4.92%
2000 17.578.000.000 2.64%
2001 27.057.000.000 35.03%
2002 24.874.000.000 -8.78%
2003 27.471.000.000 9.45%
2004 30.435.000.000 9.74%
2005 28.138.000.000 -8.16%
2006 25.575.000.000 -10.02%
2007 26.172.000.000 2.28%
2008 29.552.000.000 11.44%
2009 31.008.000.000 4.7%
2010 31.076.000.000 0.22%
2011 32.970.000.000 5.74%
2012 35.897.000.000 8.15%
2013 38.592.000.000 6.98%
2014 33.749.000.000 -14.35%
2015 31.748.000.000 -6.3%
2016 33.707.000.000 5.81%
2017 33.551.000.000 -0.46%
2018 10.659.000.000 -214.77%
2019 129.944.000.000 91.8%
2020 118.481.000.000 -9.67%
2021 109.314.000.000 -8.39%
2022 96.820.000.000 -12.9%
2023 95.159.000.000 -1.75%
2023 91.263.000.000 -4.27%
2024 94.646.000.000 3.57%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Bristol-Myers Squibb Company PFD CONV 2 Liabilities
Year Liabilities Growth
1987 2.759.000.000
1988 3.325.000.000 17.02%
1989 3.413.000.000 2.58%
1990 3.797.000.000 10.11%
1991 3.621.000.000 -4.86%
1992 4.784.000.000 24.31%
1993 6.161.000.000 22.35%
1994 7.206.000.000 14.5%
1995 8.107.000.000 11.11%
1996 8.115.000.000 0.1%
1997 7.758.000.000 -4.6%
1998 8.696.000.000 10.79%
1999 8.469.000.000 -2.68%
2000 8.398.000.000 -0.85%
2001 16.321.000.000 48.54%
2002 15.907.000.000 -2.6%
2003 17.685.000.000 10.05%
2004 20.233.000.000 12.59%
2005 16.930.000.000 -19.51%
2006 15.584.000.000 -8.64%
2007 15.610.000.000 0.17%
2008 17.311.000.000 9.83%
2009 16.223.000.000 -6.71%
2010 15.438.000.000 -5.08%
2011 17.103.000.000 9.74%
2012 22.259.000.000 23.16%
2013 23.356.000.000 4.7%
2014 18.766.000.000 -24.46%
2015 17.324.000.000 -8.32%
2016 17.360.000.000 0.21%
2017 21.704.000.000 20.01%
2018 7.349.000.000 -195.33%
2019 78.246.000.000 90.61%
2020 80.599.000.000 2.92%
2021 73.308.000.000 -9.95%
2022 65.702.000.000 -11.58%
2023 65.674.000.000 -0.04%
2023 62.201.000.000 -5.58%
2024 77.577.000.000 19.82%

Bristol-Myers Squibb Company PFD CONV 2 Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
22.94
Net Income per Share
-3.23
Price to Earning Ratio
-246.67x
Price To Sales Ratio
2.35x
POCF Ratio
113.92
PFCF Ratio
8.44
Price to Book Ratio
94.83
EV to Sales
3.38
EV Over EBITDA
8.39
EV to Operating CashFlow
11.08
EV to FreeCashFlow
12.13
Earnings Yield
-0
FreeCashFlow Yield
0.12
Market Cap
109,26 Bil.
Enterprise Value
156,97 Bil.
Graham Number
24.69
Graham NetNet
-28.63

Income Statement Metrics

Net Income per Share
-3.23
Income Quality
-2.17
ROE
-0.28
Return On Assets
-0.08
Return On Capital Employed
0.12
Net Income per EBT
1.05
EBT Per Ebit
-0.79
Ebit per Revenue
0.18
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0.2
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.7
Operating Profit Margin
0.18
Pretax Profit Margin
-0.15
Net Profit Margin
-0.15

Dividends

Dividend Yield
0
Dividend Yield %
0.33
Payout Ratio
-0.73
Dividend Per Share
2.6

Operating Metrics

Operating Cashflow per Share
6.99
Free CashFlow per Share
6.39
Capex to Operating CashFlow
0.09
Capex to Revenue
0.03
Capex to Depreciation
0.12
Return on Invested Capital
0.16
Return on Tangible Assets
-0.15
Days Sales Outstanding
118.86
Days Payables Outstanding
100.96
Days of Inventory on Hand
82.82
Receivables Turnover
3.07
Payables Turnover
3.62
Inventory Turnover
4.41
Capex per Share
0.6

Balance Sheet

Cash per Share
3,28
Book Value per Share
8,42
Tangible Book Value per Share
-17.02
Shareholders Equity per Share
8.39
Interest Debt per Share
26.69
Debt to Equity
3.09
Debt to Assets
0.56
Net Debt to EBITDA
2.55
Current Ratio
1.16
Tangible Asset Value
-34,50 Bil.
Net Current Asset Value
-50,69 Bil.
Invested Capital
63357000000
Working Capital
3,63 Bil.
Intangibles to Total Assets
0.54
Average Receivables
14,60 Bil.
Average Payables
3,65 Bil.
Average Inventory
3031000000
Debt to Market Cap
0.48

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Bristol-Myers Squibb Company PFD CONV 2 Dividends
Year Dividends Growth
2004 2
2005 2 0%
2006 2 0%
2007 2 0%
2008 2 0%
2009 2 0%
2010 2 0%
2011 2 0%
2012 2 0%
2013 2 0%
2014 2 0%
2015 2 0%
2016 2 0%
2017 2 0%
2018 2 0%
2019 2 0%
2020 2 0%
2021 2 0%
2022 2 0%
2023 2 0%
2024 3 0%

Bristol-Myers Squibb Company PFD CONV 2 Profile

About Bristol-Myers Squibb Company PFD CONV 2

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

CEO
Employee
0
Address

,

Bristol-Myers Squibb Company PFD CONV 2 Executives & BODs

Bristol-Myers Squibb Company PFD CONV 2 Executives & BODs
# Name Age

Bristol-Myers Squibb Company PFD CONV 2 Competitors

Novartis AG Logo
Novartis AG

NVSEF

(2.2)
Astellas Pharma Inc. Logo
Astellas Pharma Inc.

ALPMF

(2.2)
Roche Holding AG Logo
Roche Holding AG

RHHVF

(2.2)
Astellas Pharma Inc. Logo
Astellas Pharma Inc.

ALPMY

(2.0)
AstraZeneca PLC Logo
AstraZeneca PLC

AZNCF

(2.8)
Roche Holding AG Logo
Roche Holding AG

RHHBY

(2.5)
GSK plc Logo
GSK plc

GSK

(2.2)
Novartis AG Logo
Novartis AG

NVS

(2.0)
Sanofi Logo
Sanofi

SNY

(3.0)
AstraZeneca PLC Logo
AstraZeneca PLC

AZN

(3.0)